Skip to main content

Table 1 Drug-related adverse events occurring in ≥ 5% of evaluable patients at grade III or greater

From: Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies

Drug-related adverse events categorized by SOC and PT

Number of patients with grade I/II at > 5% incidence

Number of patients with ≥ grade III

Hematological

  

Neutropenia

17 (68.0)

11 (44.0)

Leukopenia

11 (44.0)

2 (8.0)

Thrombocytopenia

5 (20.0)

1 (4.0)

Lymphocythemia

3 (12.0)

2 (8.0)

Anemia

3 (12.0)

0

Leukocytosis

2 (8.0)

0

Non-hematological

  

Elevated serum lactate dehydrogenase

11 (44.0)

1 (4.0)

Elevated serum α-hydroxybutyrate dehydrogenase

6 (24.0)

1 (4.0)

Hyperuricemia

5 (20.0)

3 (12.0)

Upper respiratory tract infection

4 (16.0)

1 (4.0)

Pneumonia

4 (16.0)

4 (16.0)

Proteinuria

4 (16.0)

0

Hyperbilirubinemia

3 (12.0)

0

Elevated alanine aminotransferase

3 (12.0)

0

Elevated aspartate aminotransferase

2 (8.0)

0

Elevated serum alkaline phosphatase

3 (12.0)

0

Weight loss

3 (12.0)

0

Pneumonitis

3 (12.0)

2 (8.0)

Weight gain

2 (8.0)

1 (4.0)

Elevated γ-glutamyltransferase

2 (8.0)

0

Elevated bilirubin

2 (8.0)

0

Diarrhea

2 (8.0)

0

Cough

2 (8.0)

0

Oropharyngeal pain

2 (8.0)

0

Maculopapule

2 (8.0)

0

Fever

2 (8.0)

0

Fatigue

2 (8.0)

0

  1. AE adverse event, SOC system organ class, PT preferred term